Climb Bio
CLYM
65 hedge funds and large institutions have $157M invested in Climb Bio in 2025 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 21 increasing their positions, 21 reducing their positions, and 18 closing their positions.
75% more capital invested
Capital invested by funds: $89.7M → $157M (+$67.7M)
0% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 21
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
4% less funds holding
Funds holding: 68 → 65 (-3)
20.08% less ownership
Funds ownership: 65.87% → 45.79% (-20%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$6.42M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.35M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$3.12M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.35M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$48.3M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.01M |
| 3 |
CF
Cantor Fitzgerald
New York
|
-$1.1M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.02M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$976K |
CLYM Hedge Fund Activity: Q4 2025 in Review
65 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q4 2025, worth a combined $157M — up 75% from $89.7M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CLYM and 17 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 21 added.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $6.42M. The largest seller was RA Capital Management, cutting an estimated $48.3M.
- 65 institutional investors held Climb Bio (CLYM) as of Q4 2025, down from 68 in Q3 2025.
- Funds reported $157M of Climb Bio stock for Q4 2025, up 75% quarter-over-quarter.
- 17 funds opened new Climb Bio positions in Q4 2025 and 18 closed out, a net change of -1 holder.
- The largest Climb Bio buyer in Q4 2025 was MPM BioImpact, an estimated $6.42M added.
- The largest Climb Bio seller in Q4 2025 was RA Capital Management, an estimated $48.3M sold.
Based on aggregated 13F filings for Q4 2025.